Japan’s Takeda suspends new clinical trials in Russia and halts new investments in Russia, Supplies of drugs and clinical trials will continue. Takeda has taken further action to discontinue activities in Russia that are not essential to maintaining supply of medicines to patients and providing ongoing support to employees. This includes suspending all new investments, suspending advertising and promotion, not initiating new clinical trials and stopping enrollment of new patients in ongoing clinical trials. Despite statements about halting investments and transferring its manufacturing asset, Takeda continues to maintain an operational presence in Russia. The active Head of Legal Russia vacancy on the company’s official careers site indicates ongoing business operations requiring full legal and regulatory support.